Kala Pharmaceuticals, Inc. (0JQ2.L)
USD 3.79
(-0.94%)
USD 3.79
(-0.94%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -36.08 Million USD | 52.4% |
| 2022 | -36.69 Million USD | 23.75% |
| 2021 | -131.95 Million USD | -11.81% |
| 2020 | -92.9 Million USD | -11.5% |
| 2019 | -83.25 Million USD | -36.22% |
| 2018 | -62.46 Million USD | -60.2% |
| 2017 | -40.54 Million USD | -22.1% |
| 2016 | -32.1 Million USD | -106.36% |
| 2015 | -15.74 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -11.7 Million USD | -45.1% |
| 2024 Q2 | -9.57 Million USD | 21.64% |
| 2023 Q1 | -11.36 Million USD | -11.75% |
| 2023 Q3 | -8.76 Million USD | -2.31% |
| 2023 Q2 | -8.56 Million USD | 24.64% |
| 2023 FY | - USD | 52.4% |
| 2023 Q4 | -9.27 Million USD | -5.81% |
| 2022 FY | - USD | 23.75% |
| 2022 Q4 | -10.16 Million USD | 25.79% |
| 2022 Q3 | -13.7 Million USD | 48.49% |
| 2022 Q2 | -26.6 Million USD | 13.31% |
| 2022 Q1 | -30.68 Million USD | -25.41% |
| 2021 Q1 | -28.02 Million USD | 3.18% |
| 2021 Q3 | -25.79 Million USD | 10.29% |
| 2021 Q4 | -24.46 Million USD | 5.15% |
| 2021 Q2 | -28.75 Million USD | -2.62% |
| 2021 FY | - USD | -11.81% |
| 2020 Q2 | -21.17 Million USD | -8.07% |
| 2020 Q4 | -28.94 Million USD | -13.18% |
| 2020 Q1 | -19.59 Million USD | 1.09% |
| 2020 FY | - USD | -11.5% |
| 2020 Q3 | -25.57 Million USD | -20.74% |
| 2019 Q1 | -22.68 Million USD | 0.18% |
| 2019 FY | - USD | -36.22% |
| 2019 Q4 | -19.81 Million USD | 4.61% |
| 2019 Q3 | -20.77 Million USD | 4.57% |
| 2019 Q2 | -21.76 Million USD | 4.07% |
| 2018 Q2 | -14.02 Million USD | -30.35% |
| 2018 Q1 | -10.75 Million USD | 1.22% |
| 2018 Q3 | -15 Million USD | -7.03% |
| 2018 Q4 | -22.72 Million USD | -51.47% |
| 2018 FY | - USD | -60.2% |
| 2017 Q1 | -9.45 Million USD | 4.01% |
| 2017 Q2 | -9.52 Million USD | -0.7% |
| 2017 FY | - USD | -22.1% |
| 2017 Q4 | -10.88 Million USD | -17.5% |
| 2017 Q3 | -9.26 Million USD | 2.68% |
| 2016 Q4 | -9.85 Million USD | -2.47% |
| 2016 Q2 | -7.76 Million USD | -55.25% |
| 2016 Q1 | -4.99 Million USD | 0.0% |
| 2016 Q3 | -9.61 Million USD | -23.88% |
| 2016 FY | - USD | -106.36% |
| 2015 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| uniQure N.V. | -253.1 Million USD | 85.744% |
| Abeona Therapeutics Inc. | -50.57 Million USD | 28.652% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | 58.991% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | 89.556% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 86.435% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 69.331% |
| Imunon, Inc. | -20.78 Million USD | -73.619% |
| Dynavax Technologies Corporation | 9.66 Million USD | 473.288% |
| Editas Medicine, Inc. | -163.11 Million USD | 77.88% |
| FibroGen, Inc. | -261.4 Million USD | 86.197% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | 91.964% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 108.671% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 91.785% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 136.72% |
| Verastem, Inc. | -83.16 Million USD | 56.614% |
| Zoetis Inc. | 3.68 Billion USD | 100.979% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 100.784% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | 58.729% |
| Homology Medicines, Inc. | -47.75 Million USD | 24.445% |
| Nektar Therapeutics | -243.1 Million USD | 85.158% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 64.214% |
| Unity Biotechnology, Inc. | -37.28 Million USD | 3.221% |
| Perrigo Company plc | 646.2 Million USD | 105.584% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 75.963% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 99.68% |
| Illumina, Inc. | -608 Million USD | 94.065% |
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 100.334% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 101.108% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 65.236% |
| Waters Corporation | 1.02 Billion USD | 103.53% |
| Biogen Inc. | 2.37 Billion USD | 101.518% |
| Evolus, Inc. | -41.81 Million USD | 13.7% |
| Adicet Bio, Inc. | -136.53 Million USD | 73.573% |
| bluebird bio, Inc. | -167.16 Million USD | 78.415% |
| Geron Corporation | -174.78 Million USD | 79.356% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | 84.183% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 60.814% |
| Myriad Genetics, Inc. | -67.8 Million USD | 46.782% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 92.874% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | 103.1% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | 18.801% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 111.629% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 100.775% |
| Agilent Technologies, Inc. | 1.67 Billion USD | 102.152% |
| OPKO Health, Inc. | -65.51 Million USD | 44.926% |
| Exelixis, Inc. | 196.6 Million USD | 118.353% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 133.309% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 35.286% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 83.963% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 84.313% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 107.984% |
| Blueprint Medicines Corporation | -474.61 Million USD | 92.398% |
| Insmed Incorporated | -654.73 Million USD | 94.489% |
| TG Therapeutics, Inc. | 26.1 Million USD | 238.245% |
| Incyte Corporation | 919.42 Million USD | 103.924% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 92.859% |